Goldman Sachs analysts removed Zai Lab (ZLAB) from the firm’s APAC Conviction List as part of its monthly update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLAB:
- Promising Clinical Results and Strategic Developments Drive Buy Rating for Zai Lab
- Zai Lab Secures RMB300 Million Debt Facility
- Zai Lab falls -6.9%
- Zai Lab’s Strategic Positioning and Competitive Edge in SCLC Treatment Justifies Buy Rating
- Zai Lab to wait on results of FORTITUDE-102 prior to regulatory filing